Which peptides are studied for cancer?
Short answer
11 profiles here are grouped under “Cancer”: 10 FDA-approved and 1 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 10
FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products13,14,15,16,17,18
FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.13,14,16
Is leuprolide FDA-approved? · Leuprolide vs Triptorelin · Goserelin vs Leuprolide
FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors19,20
FDA-approved. Drugs@FDA lists Lutathera, NDA 208700, with an original approval date of January 26, 2018, and a second product, Bexlutry, NDA 218525, approved September 14, 2026. The cited label has no boxed warning.19,20,21
Not FDA-approved 1
Not FDA-approved; FDA advised against adding it to the compounding list31,32,33
Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.31,33
Is thymosin alpha-1 FDA-approved? · Thymosin alpha-1 vs Thymosin beta-4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: KYPROLIS (carfilzomib), NDA 202714 · original approval July 20, 2012 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2KYPROLIS (carfilzomib) for injection · SPL version 59 · published 2025-06-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 3FIRMAGON (degarelix) kit · SPL version 18 · published 2024-02-01 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: FIRMAGON (degarelix acetate), NDA 022201 · original approval December 24, 2008 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5Drugs@FDA: NETSPOT (gallium dotatate Ga-68), NDA 208547 · original approval June 1, 2016 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 6NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) · SPL version 23 · published 2026-07-07 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 7ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 8Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 9Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 10Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 11Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 12Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 13ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 14Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 15Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 16Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 17Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 18Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗
Drugs@FDA via openFDA · Official source · Source checked November 15, 2026
- 19LUTATHERA (lutetium Lu 177 dotatate) injection · SPL version 12 · published 2026-01-16 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 20Drugs@FDA: LUTATHERA (lutetium Lu-177 dotatate), NDA 208700 · original approval January 26, 2018 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 21Drugs@FDA: BEXLUTRY (lutetium Lu-177 dotatate), NDA 218525 · original approval September 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 22APHEXDA (motixafortide) for injection · SPL version 3 · published 2026-10-19 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 23Drugs@FDA: APHEXDA (motixafortide acetate), NDA 217159 · original approval September 8, 2023 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 24Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 25Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 26Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 27Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 28Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 29TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 30Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 31FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 32December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 33Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026